| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CCL8 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3-4条关于CCL8抗体的虚构参考文献示例(基于领域常见研究方向，非真实文献)：
---
1. **文献名称**: *"CCL8-neutralizing antibody reduces tumor metastasis by inhibiting macrophage recruitment in breast cancer"*
**作者**: Li X, et al.
**摘要**: 本研究利用抗CCL8单克隆抗体阻断肿瘤微环境中CCL8趋化因子信号，发现其显著抑制巨噬细胞向肿瘤部位的浸润，从而降低乳腺癌小鼠模型的肺转移，提示CCL8抗体在抗肿瘤免疫中的潜在价值。
---
2. **文献名称**: *"Targeting CCL8 in chronic viral infection: Antibody-mediated suppression improves T cell exhaustion"*
**作者**: Smith J, et al.
**摘要**: 通过慢性LCMV感染模型，验证抗CCL8抗体可减少持续炎症导致的T细胞耗竭，恢复抗病毒T细胞功能，为慢性病毒感染治疗提供新策略。
---
3. **文献名称**: *"CCL8 blockade alleviates neuroinflammation by modulating microglial activation in Alzheimer's disease models"*
**作者**: Wang Y, et al.
**摘要**: 在阿尔茨海默病小鼠模型中，抗CCL8抗体通过抑制小胶质细胞异常活化及促炎因子释放，减轻神经炎症并改善认知功能障碍，表明CCL8是神经退行性疾病的重要干预靶点。
---
4. **文献名称**: *"Anti-CCL8 antibody therapy attenuates pulmonary fibrosis via disrupting fibroblast-immune cell crosstalk"*
**作者**: Gupta R, et al.
**摘要**: 研究证明CCL8抗体可阻断成纤维细胞与单核细胞之间的旁分泌信号，减少促纤维化因子分泌，从而显著改善博来霉素诱导的小鼠肺纤维化病理进程。
---
注：以上文献及作者为模拟示例，实际研究中需通过PubMed或Google Scholar检索真实发表论文。
CCL8. also known as monocyte chemoattractant protein-2 (MCP-2), is a small chemokine belonging to the CC motif family. It is encoded by the *CCL8* gene and primarily functions in immune regulation by recruiting leukocytes, including monocytes, lymphocytes, eosinophils, and basophils, to sites of inflammation or infection. CCL8 binds to chemokine receptors such as CCR1. CCR2. CCR3. and CCR5. playing roles in both acute and chronic inflammatory responses. It is implicated in various diseases, including autoimmune disorders, viral infections (e.g., HIV), fibrosis, and cancer, where it can either promote or suppress tumor progression depending on the microenvironment.
CCL8 antibodies are critical tools for studying its biological functions and therapeutic potential. These antibodies, often monoclonal or polyclonal, are designed to detect CCL8 in immunoassays (e.g., ELISA, Western blot) or neutralize its activity in experimental models. By blocking CCL8-receptor interactions, researchers explore its role in immune cell trafficking, inflammation resolution, and disease pathogenesis. Recent studies highlight CCL8 as a biomarker in cancer immunotherapy, as its expression correlates with immune cell infiltration and response to checkpoint inhibitors. However, challenges remain in understanding its context-dependent roles and developing selective therapeutic antibodies with minimal off-target effects. Ongoing research aims to clarify CCL8's dualistic functions and harness its pathway for treating inflammatory diseases or modulating antitumor immunity.
×
